Skip to content

The effects of Warfarin on permacath function

Evaluating the effects of Warfarin on permacath function in hemodialysis patients

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200516047461N1
Enrollment
86
Registered
2020-05-20
Start date
2020-01-05
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease. Chronic kidney disease (CKD)

Interventions

Intervention 1: Intervention group: According to the inclusion and exclusion criteria 86 patients (43 in the intervention group and 43 patients in the control group) recruited. The patients are a cand

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who were a candidate for the second time embedding of permanent arteriovenous catheters Informed consent to participate in the study Age above 18 years old

Exclusion criteria

Exclusion criteria: History of major hemorrhages (requiring blood transfusion, retroperitoneal or intracranial hemorrhage, inducing hypovolemia, leading to more than two units decrease in hemoglobin) within the previous three months Progressive diabetic retinopathy Less than 12 months of life-expectancy because of systemic disease or malignancies Poorly controlled hypertension (systolic blood pressure>200 mmHg or diastolic blood pressure>100 mmHg measured three times within two weeks) Absolute platelet count less than 100000 International normalized ratio (INR)=1.3 Partial thrombin time (PTT)= 5 folds than the normal range Hypersensitivity to Warfarin Active peptic ulcer Pregnancy or lactation Documented aortic aneurysm

Design outcomes

Primary

MeasureTime frame
Permcath function. Timepoint: In every hemodialysis session. Method of measurement: Catheter clotting defined as the gross visible occlusion of the catheter or the dialysis performance with less than 250 ml per minute velocity.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMilad Golshani nasab

Esfahan University of Medical Sciences

milad.golshani@gmail.com+98 31 3668 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026